Exome sequencing reveals aggregates of rare variants in glycosyltransferase and

other genes influencing immunoglobulin G and transferrin glycosylation 2

- Arianna Landini^{1,2}, Paul R.H.J. Timmers^{1,2}, Azra Frkatović-Hodžić³, Irena Trbojević-4
- Akmačić³, Frano Vučković³, Tea Pribić, Regeneron Genetics Center⁴, Gannie Tzoneva⁴, Alan 5
- R. Shuldiner⁴, Ozren Polašek^{5,6}, Caroline Hayward¹, Gordan Lauc^{3,7}, James F. Wilson^{*1,2} & 6
- Lucija Klarić*1 7

1

3

17

20

- 8 1 MRC Human Genetics Unit, Institute for Genetics and Cancer, University of Edinburgh,
- 9 Edinburgh, United Kingdom
- 2 Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, 10
- 11 United Kingdom
- 12 3 Genos Glycoscience Research Laboratory, Zagreb, Croatia
- 4 Regeneron Genetics Center, Tarrytown, NY, USA 13
- 14 5 Department of Public Health, School of Medicine, University of Split, Split, Croatia
- 15 6 Algebra University College, Zagreb, Croatia
- 16 7 Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
- * Authors contributed equally. 18
- 19 Correspondence to: J.F.W (jim.wilson@ed.ac.uk) or L.K. (lucija.klaric@ed.ac.uk)

21 **Abstract**

- 22 It is often difficult to be certain which genes underlie the effects seen in association studies.
- However, variants that disrupt the protein, such as predicted loss of function (pLoF) and 23
- 24 missense variants, provide a shortcut to identify genes with a clear biological link to the
- 25 interest. Glycosylation is one the phenotype of of most common post-
- 26 translationalmodifications of proteins, and an important biomarker of both disease and its
- 27 progression. Here, we utilised the power of genetic isolates, gene-based aggregation tests and
- 28 intermediate phenotypes to assess the effect of rare (MAF<5%) pLoF and missense variants
- 29 from whole exome sequencing on the N-glycome of plasma transferrin (N=1907) and
- immunoglobulin G (N=4912), and their effect on diseases. We identified significant gene-30
- 31 based associations for transferrin glycosylation at 5 genes (p<8.06x10⁻⁸) and for IgG glycan
- traits at 4 genes (p<1.19x10⁻⁷). Associations in three of these genes (FUT8, MGAT3 and 32
- RFXAP) are driven by multiple rare variants simultaneously contributing to protein 33
- glycosylation. Association at ST6GAL1, with a 300-fold up-drifted variant in the Orkney 34
- 35 Islands, was detectable by a single-point exome-wide association analysis. Glycome-associated
- 36 aggregate associations are located in genes already known to have a biological link to protein
- 37 NOTED THE ATTEMENT (FILE IT IN THE CATTON AND THE C

genes which have not been previously reported (e.g. RFXAP for IgG). To assess the potential impact of rare variants associated with glycosylation on other traits, we queried public repositories of gene-based tests, discovering a potential connection between transferrin glycosylation, MSR1, galectin-3, insulin-like growth factor 1 and diabetes. However, the exact mechanism behind these connections requires further elucidation.

38 39

40

41

42

Introduction

43

44

45

46 47

48 49

50

51

52

53

54 55

56 57

58

59 60

61

62

63

64

65

66

67

68

69

70 71

72

73

74 75

76

77

78 79

80

81

82 83 Genome-wide association studies (GWAS) have so far identified thousands of loci associated with human complex traits and diseases. However, the large majority of these variants are found in noncoding regions of the genome¹, posing a challenge when attempting to uncover their functional impact on the phenotype. On the contrary, whole-exome sequencing (WES) studies offer the opportunity to identify rare variants of larger effect on the encoded protein. such as predicted loss of function (pLoF) and missense variants, for which causal biological mechanisms are generally easier to elucidate². Methods for exome-wide rare variant analysis have been successfully employed to discover variants and genes associated with both complex molecular traits³ and diseases^{4,5}. While single-variant tests, such as GWAS, are largely adopted to explore associations of common genetic variants with phenotypes of interest, they have little power to identify rare variant associations, due to the low number of observations. Therefore, a set of methods testing cumulative effects of multiple rare variants in genetic regions, where rare variants are grouped at the gene level (also known as 'masks') via a collapsing test, such as burden tests, or variance-component tests (e.g. sequence kernel association test, SKAT⁶) were developed. In addition to increasing the statistical power by aggregating multiple rarevariants, using genetically isolated populations can provide unique opportunities for novel discovery in an association study⁷. Recent bottlenecks, restricted immigration and limited population size lead to increased genetic drift. Consequently, in such populations some otherwise rare variants can substantially increase in frequency compared to the general population, therefore increasing association power for these variants.

Glycosylation is one of the most frequent post-translational modifications, where sugar residues, called glycans, are attached to the surface of proteins. Changes in protein Nglycosylation patterns have been described in the ageing process^{8,9} and in a wide variety of complex diseases, including autoimmune diseases¹⁰, diabetes¹¹, cardiovascular diseases¹², neurodegenerative diseases¹³ and cancer¹⁴. Despite glycans having an important role in human health and serving as potential biomarkers in clinical prognosis and diagnosis 15, we have just started scratching the surface of the complex network of genes regulating protein glycosylation. All studies published to date exploring the genetic regulation of total plasma protein, immunoglobulin G (IgG) and transferrin N-glycosylation have employed single variant-based GWAS tests, mostly uncovering common variants located in non-coding regions of the genome^{16–23}. Rare variants contributing to glycan variation, and their impact on human health, thus remain unexplored.

To address this knowledge gap, we used multiple gene-based aggregation tests to investigate how rare (MAF<5%) pLoF and missense variants from whole exome sequencing affect 51 transferrin (N = 1907) and 94 IgG (N = 4912) glycan traits in European-descent cohorts. IgG is both the most abundant antibody and one of the most abundant proteins in human serum. It contains evolutionary conserved N-glycosylation sites in the constant region of each of its heavy chains, occupied by biantennary, largely core-fucosylated and partially truncated glycan structures, that may carry a bisecting N-acetylglucosamine and sialic acid residues^{24,25}. Transferrin is a blood plasma glycoprotein that binds iron (Fe) and consequently mediates its

transport through blood plasma. Human transferrin has two N-glycosylation sites, with biantennary disialylated digalactosylated glycan structure without fucose being the most abundant glycan attached^{26,27}.

84

85

86

87

88

89

90 91

92

93

94

In this study, we used gene-based aggregation of rare variants to identify several genes associated with transferrin and IgG glycosylation traits. Significant genes include known protein glycosylation genes as well as novel genes with no previously known role in posttranslational modification. Importantly, several associations would not have been detectable by single-point analysis and one association was detected thanks to enrichment of rare variants in population isolates. Finally, we highlight the impact of rare variation in these genes on healthrelated traits by performing gene-based aggregation tests of 116 health-related traits together with gene lookups in public repositories of gene-based association tests

Results

95

96

97

98

99

100 101

102

103

104

105 106

107 108

109

110

111

112

113

Exome variant annotation

To assess the effect of rare genetic variants on glycosylation of two proteins, we sequenced the exomes of 4.801 participants of European ancestry. After quality control, a total of 233,820 distinct autosomal coding genetic variants were available in the ORCADES cohort (N=2090), 244,649 in the VIKING cohort (N=2106) and 340,203 in the CROATIA-Korcula cohort (N=2872). Percentages of variants for each effect category in the total sequenced coding variation are similar across the three cohorts (Table 1). More than half (~53%) of the sequenced coding variants are missense variants, of which nearly half (~28% of total coding variation) are classified as likely or possibly deleterious by multiple variant effect predictor algorithms (see Methods). The second most represented effect category is synonymous mutations (~33%), followed by variants in splice regions (~8%), predicted loss of function (pLoF) (~4%) and inframe insertions/deletions (~1.5%). Around one quarter of coding variants in the ORCADES and VIKING cohorts are singletons (minor allele count, MAC=1); this percentage is instead higher in CROATIA-Korcula cohort (~35%), possibly due to the larger sequenced sample size.

Table 1. Number of coding exome variants sequenced in the complete sample of 3 isolated cohorts. Counts and prevalence of autosomal variants observed in WES-targeted regions across all individuals in the ORCADES, CROATIA-Korcula and VIKING cohort, by type or functional class for all and for singleton variants (MAC= 1).

	ORC	ADES (N:	=2090)	CRC	OATIA-Ko (N=2872)		VIKING (N=2106)			
Variant category	No. of variants	% of total coding variants	Variants % with MAC=1	No. of variants	% of total coding variants	Variants % with MAC=1	No. of variants	% of total coding variants	Variants % with MAC=1	
coding variants	233,820		25.1%	340,203		35.5%	244,649		28.9%	
pLOF	8639	3.69%	37.1%	12,970	3.81%	47.2%	9025	3.69%	41.4%	
Splice acceptor	872	0.37%	37.8%	1309	0.38%	45.5%	945	0.39%	42.7%	
Splice donor	1042	0.45%	37.5%	1506	0.44%	48.1%	1079	0.44%	40.4%	
Stop gained	2833	1.21%	36.8%	4171	1.23%	47%	2879	1.18%	41.8%	
Frameshift	3401	1.45%	37.8%	5274	1.55%	47.9%	3583	1.46%	42.1%	
Stop lost	151	0.06%	32.5%	244	0.07%	43%	182	0.07%	39%	
Start lost	340	0.15%	30%	466	0.14%	44.2%	357	0.15%	30.3%	
Missense	124,416	53.2%	27%	183,056	53.8%	37.6%	130,299	53.3%	30.6%	
Likely benign (0-1)	56,366	24.1%	21.8%	80,777	23.7%	31.6%	59,141	24.2%	25.4%	
Possibly deleterious (2-3)	31,693	13.5%	28.1%	47,235	13.9%	39.1%	33,138	13.5%	31.6%	

Likely deleterious (4-5)	35,728	15.3%	34.2%	54,187	15.9%	45.4%	37,384	15.3%	38.2%
Unclassified missense	629	0.27%	23%	857	0.25%	29.3%	636	0.26%	23.1%
Splice region	18,580	7.95%	24.7%	26660	7.84%	32.4%	19,297	7.89%	27.8%
In-frame indel	3383	1.45%	21.5%	5244	1.54%	29.5%	3606	1.47%	26%
Protein altering	3	0%	33.3%	4	0%	25%	2	0%	0%
Stop retained	1	0%	0%	2	0%	50%	1	0%	25.2%
Synonymous	78,798	33.7%	21.1%	112,267	33%	31.6%	82,419	33.7%	100%

Exome-wide aggregated rare variant analysis of transferrin and IgG glycomes

114

115

116

117

118

119

120 121

122

123

124

125

126 127

128

129

130

131 132

133

134

135

136 137

138

139 140

141 142

143 144 We performed exome-wide gene-based tests across 51 transferrin traits (glycome subset of CROATIA-Korcula N = 948, VIKING N = 959) and 94 IgG glycan traits (glycome subset of ORCADES N = 1960, CROATIA-Korcula N = 1866, VIKING N = 1086), testing low frequency and rare (MAF <5%) pLoF and missense variants. In total, we identified 16 significant associations for transferrin- (Supplementary Table 1) and 32 significant associations for IgG- (Supplementary table 2) glycan traits, at Bonferroni-corrected p-values of 8.06x10⁻⁸ and 1.19x10⁻⁷, respectively (Figure 1, Table 2). Most gene-aggregated rare variants were associated with protein-specific glycans (transferrin: variants in FUT6, TIRAP, MSR1 and FOXII genes, IgG: variants in MGAT3, ST6GAL1 and RFXAP genes); only FUT8 was associated with glycans from both proteins (Table 2, Supplementary Tables 1 and 2). Almost all identified genes encode key enzymes in protein glycosylation (MGAT3, ST6GAL1, FUT6, FUT8) or have been previously associated with transferrin and IgG glycan traits in GWAS analysis (MSR1, FOXI1)^{17,18}. The exceptions are TIRAP and RFXAP, which have no previously known link to protein glycosylation. We successfully replicated (p-value < 3.2x10⁻⁴ for transferrin, p-value < 5.9x10⁻⁴ for IgG) associations of glycans with low-frequency and rare variants from 4 genes - FUT6 and TIRAP with transferrin glycans, and FUT8 and MGAT3 for IgG glycans (Table 2) - as frequencies of variants in these genes are similar across the studied cohorts (Supplementary Table 3). While the associations of IgG glycans and variants from FUT8 replicated, the association of transferrin glycans with variants from the same gene did not reach the significance threshold for replication (p-value in VIKING = 1.7×10^{-3}), likely because of the 7-fold decreased frequency of the rs2229678 variant in the VIKING (MAF = 0.0056) compared to CROATIA-Korcula (MAF = 0.049) cohort (Supplementary Table 4). However, given the known biological role of FUT8 in protein glycosylation as a fucosyltransferase (one of the enzymes involved in the synthesis of glycans), we believe this association to be real. Associations of rare variants from the CROATIA-Korcula cohort in the MSR1 gene with transferrin glycosylation also did not formally replicate in the VIKING cohort (p-value = 8.6×10^{-4}) (Table 2). However, the cumulative allele count of rare variants in this gene is different between CROATIA-Korcula (MAC=46) and the VIKING cohort (MAC=38) (Supplementary Table 3), decreasing the power to replicate. We also detected a couple of

146

147

148

149 150

151

152

153

154 155

156

157

158

159

160 161

162

163

164

165

166 167 isolate-specific associations that are driven by variants increased in frequency compared to publicly accessible biobanks and variant repositories. Namely, the rs750567016 variant in ST6GAL1 that affects IgG glycosylation is more than 300 times more common in ORCADES $(MAF = 3.3 \times 10^{-3})$ than in UK Biobank $(MAF = 1.0 \times 10^{-5})$ or gnomAD $(MAF = 9.0 \times 10^{-6})$ and is absent from CROATIA-Korcula and VIKING cohorts. The rs115399307 variant in FOXII. associated with transferrin glycosylation, is seven times more common in VIKING (MAF = 2.1×10^{-2}) than in CROATIA-Korcula cohort (MAF = 2.7×10^{-3}), UK Biobank (MAF = 8.5×10^{-3}) ³) and gnomAD (MAF = 7.1×10^{-3}) (Supplementary Table 4). While the role of sialyltransferase ST6GAL1 in IgG glycosylation is well described, the roles of the transcription factor FOXII and the regulatory factor X-associated protein RFXAP still need to be confirmed and investigated.




Figure 1. Miami plot summarising the results from exome-wide gene-based tests for transferrin and IgG glycan traits. Genomic positions of the genes, calculated as the mean position of variants included in the reported mask, are labelled on the x-axis and the $-\log_{10}$ of the p-value for each rare-variants aggregating test on the y-axis. For each gene-glycan association, the lowest p-value across multiple masks, multiple variant aggregate tests and cohorts was selected for plotting. The Bonferroni-corrected significance threshold for transferrin glycan traits (horizontal red line in the top part of the plot) corresponds to 8.06x10⁻¹ ⁸, while Bonferroni-corrected threshold for the IgG glycan traits (horizontal red line in the bottom part of the plot) corresponds to 1.19x10⁻⁷. Genes significantly associated with transferrin/IgG glycan traits are indicated with a triangle and labelled, while genes not passing the significance threshold are indicated with dots.

Table 2: Gene-based rare variants associations of transferrin and IgG glycosylation.

Lead glycan	Gene	MAF	Variants	N variants	Discovery cohort	Discovery P	Assoc. test	Discovery MAF	Discovery AC	Repl. cohort	Repl. P	Repl. MAF	Repl. AC	No. of glycans
Transferrin														
TfGP20	FUT8	<0.05	pLoF and deleterious (1/5)*	6	CROATIA- Korcula	6.29x10 ⁻²⁰	Burden	0.0111	124	VIKING	1.73x10 ⁻³	0.0042	8	3
TfGP32	FUT6	<0.05	pLoF and deleterious (1/5)*	5	CROATIA- Korcula	4.31x10 ⁻¹⁸	SKAT	0.0097	90	VIKING	1.56x10 ⁻¹⁴	0.0072	96	8
TfGP35	MSR1	< 0.05	pLoF	3	CROATIA- Korcula	6.93x10 ⁻¹⁷	Burden	0.0083	46	VIKING	8.64x10 ⁻⁴	0.01	38	2
TfGP17	TIRAP	<0.05	pLoF and deleterious (1/5)*	3	VIKING	2.17x10 ⁻¹⁰	SKAT-O	0.0077	44	CROATIA- Korcula	8.12x10 ⁻⁹	0.0076	98	2
TfGP23	FOXII	<0.05	pLoF and missense	3	VIKING	1.37x10 ⁻⁸	SKAT-O	0.0074	42	CROATIA- Korcula	1.56x10 ⁻²	0.0014	8	1
IgG														
FG2S1/ (FG2+FG2S1+FG2S2)	ST6GAL1	<0.01	pLoF and missense	2	ORCADES	9.82x10 ⁻²²	Burden	0.0019	15	-	-	-	-	9
Fn/(Bn+FBn)	MGAT3	<0.01	pLoF and deleterious (1/5)*	4	ORCADES	2.31x10 ⁻¹⁰	SMMAT- E	0.0021	33	CROATIA- Korcula	6.57x10 ⁻⁹	0.0012	29	17
FG1n total/G1n	FUT8	<0.05	pLoF and missense	7	CROATIA- Korcula	6.74x10 ⁻⁸	Burden	0.0072	177	ORCADES	3.04x10 ⁻⁶	0.0037	43	5

GP21	RFXAP	<0.01	pLoF and missense	2	ORCADES	1.04x10 ⁻⁷	SMMAT- E	0.0033	26	VIKING	6.29x10 ⁻²	0.0009	2	1	
------	-------	-------	----------------------	---	---------	-----------------------	-------------	--------	----	--------	-----------------------	--------	---	---	--

Lead glycan - glycan trait reporting the strongest rare-variants association at the gene. Gene – gene for which rare variants are grouped. MAF - the highest allele frequency of variants aggregated for the mask. Variants - functional consequence of variants in the mask, aggregated in the given gene (pLoF – predicted loss of function: * denotes the number of algorithms predicting the missense variant to be deleterious). N variants - number of variants included in the mask. Discovery cohort - cohort reporting the lower p-value for the glycan-gene association. Discovery/Repl. P - p-value of the gene-based association with the lead glycan trait in the discovery/replication cohort. Assoc. test – gene-based association test for which p-value is reported. Discovery/repl. MAF - mean minor allele frequency of variants from the mask in the discovery/replication cohort. Repl. Cohort cohort reporting the higher p-value for the glycan-gene association. No. of glycans - number of other glycan traits associated with variants from the same mask. Results for transferri glycome are reported at the top of the table, while results for IgG glycome are reported at the bottom of the table. Discovery significance threshold is 8.06×10^{-8} for transferrin and 1.19×10^{-7} for IgG glycans. Replication significance threshold is 3.23×10^{-4} for transferrin and 5.95×10^{-4} for IgG glycans.

IgG glycans gene-based aggregation meta-analysis

- To further increase statistical power, we performed gene-based aggregation meta-analysis of 171
- IgG glycan traits for ORCADES and VIKING cohorts. In addition to two genes already found 172
- to be associated with IgG in the cohort-specific analysis (MGAT3 and ST6GAL1), the combined 173
- analysis of VIKING and ORCADES cohort added FUT6 to the list of genes whose rare variants 174
- are significantly (p-value<1.19x10⁻⁷) associated with IgG glycan traits (Supplementary Table 175
- 5). FUT6 is another gene known to be involved in glycosylation 17,20,22,23, encoding a 176
- glycosyltransferase enzyme that catalyses the transfer of fucose moieties to a growing glycan 177
- 178 chain.

179

180

170

Genetic architecture of aggregated effects of rare-variants

- To better understand the genetic architecture of identified associations, we next assessed 181
- 182 whether our findings could be discoverable within a GWAS framework and whether they are
- driven by single variants or multiple rare variants working in concert to affect levels of 183
- transferrin/IgG glycosylation. 184
- We first performed GWAS on imputed genotypes for each glycan trait and then repeated the 185
- 186 rare variant association tests incorporating the dosages of GWAS sentinel SNPs as additional
- covariates. Genome-wide significant (transferrin p-value<1.61x10⁻⁹, IgG p-value<2.38x10⁻⁹) 187
- associations reported in this study (Supplementary Table 6 for transferrin glycans and 188
- Supplementary Table 7 for IgG glycans) have been described in further details in Landini et 189
- al. 18 and Klarić et al. 17. Overall, aggregated associations with variants from 3 out of 8 genes, 190
- FUT8, ST6GAL1 and MGAT3, remained significant (p-value <8.06x10⁻⁸ for transferrin and p-191
- value<1.19x10⁻⁷ for IgG) after conditioning on sentinel GWAS associations (Table 3). For one 192
- 193 gene, RFXAP, there were no significant associations in the GWAS analysis, while the
- remaining four gene-based associations (FUT6, MSR1, FOXI1 and TIRAP) were explained by 194
- sentinel GWAS variants. For two of these genes, FUT6 and FOXII, the GWAS sentinel 195
- variants are low frequency (0.02<MAF<0.05; Supplementary Table 8). More specifically, for 196
- transferrin glycans, 14 out of the 16 glycome-gene aggregate pairs fail to reach genome-wide 197
- significance (p-value <8.06x10⁻⁸) after conditioning on GWAS sentinel SNPs (Supplementary 198
- 199 Table 9), meaning that a considerable part of the rare variant signal was dependent on variants
- 200 identifiable by GWAS. In contrast, for IgG glycans, 24 of the 32 glycome-gene aggregate pairs
- 201 remained significant (p-value<1.19x10⁻⁷), even after adjusting for GWAS sentinel SNPs
- 202 (Supplementary Table 10).
- 203 Next, we performed single-point exome-wide association analysis (ExWAS) and repeated the
- aggregated rare variant association tests while conditioning on the sentinel ExWAS 204
- associations. In this way we tested whether the rare-variants associations with glycosylation 205
- were driven by a single variant (i.e. showed an attenuated signal after conditioning on the 206
- 207 sentinel ExWAS variant) or were actually affected by multiple rare variants in concert (i.e.
- associations remain significant after the conditioning). Two of the associations, between 208

210 211

212

213

214 215

216 217

218

219

220

221

222

223 224

225

226

227

variants in the FUT8 gene and IgG glycans, and variants in the MGAT3 gene and transferrin glycans, remain significant after conditioning on the sentinel ExWAS variant (Table 3). Upon closer inspection, for both of these genes, the sentinel ExWAS variant was a common variant that is also an eQTL for the gene in blood (eQTLGen²⁸: rs35949016, FUT8 eQTL, p-value = 6.5×10^{-159} ; rs6001566, MGAT3 eQTL p-value = 3.9×10^{-230}) (Supplementary Table 8). Hence, it appears that glycosylation is affected by common variants and independently by aggregates of rare variants in these two genes. Indeed, by looking at the single-point effects of each rare variant from the mask, we can see that multiple independent rare variants contribute to the effect on glycosylation levels (Supplementary Table 11).

In summary, four of the identified associations, three with low-frequency variants from FUT6, MSR1 and FOXI1 and one with a common variant from the TIRAP gene, could have been discovered using a GWAS of imputed genotype data. On the other hand, the rare variant association at ST6GAL1 gene could only have been discovered using an ExWAS, as it is too rare to be imputed well. Finally, associations with variants from two genes, FUT8 and MGAT3, are driven by multiple rare variants simultaneously contributing to glycosylation of IgG and transferrin. Also the rare variant association at RFXAP gene could not have been discovered by either GWAS or ExWAS as there were no significant single-point associations. However, it is important to note that we could not replicate this association because the variants from its mask are depleted in the other studied cohorts (Supplementary Table 4).

Table 3: Genetic architecture of aggregated effect of rare variant associations when conditioning on sentinel variants from GWAS or ExWAS analysis. Two associations, those with variants from the *FUT8* and *MGAT3* regions remain significant after conditioning on GWAS/ExWAS sentinel variants. Associations with variants from the *MSR1* gene are dependent on both GWAS and ExWAS sentinel variants. The association with variants from the *ST6GAL1* gene is driven by the sentinel ExWAS variant, which was not present in the imputed GWAS.

Lead glycan	Gene	MAF	Variants	Association test	cohort	Discovery P	GWAS adj p	ExWAS adj p
Transferrin						•		•
TfGP20	FUT8	<0.05	pLoF and deleterious (1/5)*	Burden	CROATIA- Korcula	6.29x10 ⁻²⁰	2.75x10 ⁻¹²	2.70 x10 ⁻¹⁵
TfGP32	FUT6	<0.05	pLoF and deleterious (1/5)*	SKAT	CROATIA- Korcula	4.31x10 ⁻¹⁸	3.07x10 ⁻¹	2.94 x10 ⁻¹
TfGP35	MSR1	< 0.05	pLoF	Burden	CROATIA- Korcula	6.93x10 ⁻¹⁷	6.62x10 ⁻⁷	3.70 x10 ⁻³
TfGP17	TIRAP	<0.05	pLoF and deleterious (1/5)*	SKAT-O	VIKING	2.17x10 ⁻¹⁰	8.61x10 ⁻¹	1.38 x10 ⁻¹
TfGP23	FOXI1	< 0.05	pLoF and missense	SKAT-O	VIKING	1.37x10 ⁻⁰⁸	6.85x10 ⁻¹	6.38 x10 ⁻¹
IgG								
FG2S1/(FG2+F G2S1+FG2S2)	ST6GAL1	<0.01	pLoF and missense	Burden	ORCADES	9.82x10 ⁻²²	6.99x10 ⁻¹⁹	1.44 x10 ⁻²
Fn/(Bn+FBn)	MGAT3	<0.01	pLoF and deleterious (1/5)*	SMMAT-E	ORCADES	2.31x10 ⁻¹⁰	5.47x10 ⁻¹⁰	5.68 x10 ⁻¹⁰
FG1n total/G1n	FUT8	< 0.05	pLoF and missense	Burden	CROATIA- Korcula	6.74x10 ⁻⁸	2.31x10 ⁻⁶	8.4x10 ⁻⁶
GP21	RFXAP	<0.01	pLoF and missense	SMMAT-E	ORCADES	1.04x10 ⁻⁷	1.04x10 ⁻⁷ **	1.04x10 ⁻⁷ **

Lead glycan - glycan trait reporting the strongest rare-variants association at the gene. Gene – gene for which rare variants are grouped. MAF - the highest allele frequency of variants aggregated for the mask. Variants - functional consequence of variants in the mask, aggregated in the given gene (pLoF – predicted loss of function: * denotes the number of algorithms predicting the missense variant to be deleterious). Association test – gene-based association test for which p-value is reported. Cohort - cohort reporting the lower p-value for the glycan-gene association. Discovery P - p-value of the gene-based association test with the lead glycan trait in the cohort. GWAS adj p – p-value of association test when conditioning on the significant variants from the GWAS analysis; ** no significant GWAS variants were found. ExWAS adj p – p-value of association test when conditioning on

the significant variants from the ExWAS analysis; ** no significant ExWAS variants were found. Results for transferri glycome are reported at the top of the table, while results for IgG glycome are reported at the bottom of the table. P-value significance threshold is 8.06x10⁻⁸ for transferrin and 1.19x10⁻⁷ for IgG glycans.

Links to health-related traits

233

240 241

242

243 244

245

246

247

248

249 250

251

252

253 254

255

We next wanted to assess the potential impact of rare protein glycosylation variants on health. 234 Since some of the gene-glycan associations are population-specific, stemming from the genetic 235 drift in isolated populations, we first performed "gene-level PheWAS" with quantitative health-236 237 related traits measured in studied cohorts. At the same time, since these cohorts, because of their sample size, might be underpowered to detect associations with common diseases, we 238 queried public repositories of aggregated rare-variants associations for these genes. 239

We performed exome-wide "gene-level PheWAS" with 116 quantitative health-related traits measured in the ORCADES, CROATIA-Korcula and VIKING cohorts, limited to the genes containing pLoF and missense variants that were associated with transferrin or IgG glycome variation (Table 2). When possible, we sought to perform the analysis in the same cohort where the glycan-gene association was discovered. The only significant (p-value<5.4×10⁻⁵) association was with transferrin glycosylation-associated rare variants from the MSR1 gene and blood levels of HbA1c in the VIKING cohort (Supplementary Table 12). However, the association with HbA1c levels is not significant in CROATIA-Korcula, the cohort where we discovered the connection between MSR1 and transferrin glycosylation, and it also does not replicate in ORCADES, suggesting that it might be a false positive association. We next checked whether any of the glycome-associated genes were significantly associated with health-related traits in UK Biobank. We used two repositories of aggregated rare-variants associations: Genebass²⁹ and the AstraZeneca PheWAS portal³⁰. Missense variants from the MSR1 gene were significantly associated with insulin-like growth factor 1 levels (IGF1) in both Genebass (SKAT-O p-value = 4.6×10^{-10}) and the PheWAS portal (p-value = 1.6×10^{-24} , for the "ptv5pcnt" collapsing model).

Discussion

256

257

258

259

260

261

262 263

264

265

266

267

268 269

270

271

272

273 274

275 276

277

278 279

280

281

282

283

284

285 286

287 288

289

290

291 292

293

294

295

Statistical power to detect associations with rare genetic variants can be increased by aggregating the association signals across multiple rare variants in a gene³¹, or by using genetically isolated populations where, due to genetic drift, some variants are increased in frequency compared to a general population³². Further, intermediate phenotypes, more proximal to the genes and consequently more strongly influenced by them, can be used as "proxies' of complex diseases to boost power. Glycosylation, one of the most common posttranslational modifications, is one such intermediate phenotype and has been implicated in many diseases 10,13,14. Here, we utilised the power of genetic isolates, aggregation of multiple rare variants and intermediate phenotypes to study the effect of rare variants on glycosylation of two proteins and their effect on disease.

We performed multiple gene-based aggregation tests to assess associations with transferrin (N = 1907) and IgG (N = 4912) glycan traits in three isolated cohorts of European descent, testing rare (MAF<5%) pLoF and missense variants from whole exome sequencing. We found rare variants from 8 genes contributing to glycan levels of either IgG or transferrin. As previously observed in GWAS using imputed genotypes, transferrin and IgG glycans showed mostly protein-specific gene-based associations¹⁸, including genes encoding known glycosylation enzymes (transferrin - TIRAP, a gene in the proximity of ST3GAL4; IgG - ST6GAL1 and MGAT3), transcription factors (transferrin - FOXII), as well as other genes (transferrin - MSR1; IgG - RFXAP). On the other hand, rare variants in FUT8 and FUT6, genes encoding fucosyltransferase enzymes adding core and antennary fucose structures to the synthesised glycan, were associated with glycosylation of both proteins. Previously we showed that, while glycosylation of both transferrin and IgG proteins is associated with genes encoding FUT6 and FUT8 fucosylation enzymes, these associations are driven by independent, protein-specific variants mapped to the regulatory region of the two genes¹⁸. Accordingly, here we identified rare variants in the exonic portions of FUT8 and FUT6, acting independently or in concert with GWAS-identifiable variants.

We successfully replicated 4 gene-glycan associations (FUT6, FUT8, TIRAP and MGAT3); however, noting variants in certain genes were lower in frequency (MSR1 and FOXII) or completely absent (ST6GAL1 and RFXAP) in replication cohorts, we were underpowered to replicate the glycan associations with the remaining four genes. Two of the 8 identified associations, the ones with variants from the FUT8 and MGAT3 genes, were driven by multiple rare variants simultaneously contributing to protein glycosylation. The association with variants from the ST6GAL1 gene would have been discovered using single-point ExWAS (but not GWAS). Interestingly, for all three of these genes, we have also detected common variants independently affecting IgG and transferrin glycans. While four associations (TIRAP, FUT6, MSR1 and FOXI1) could have been discovered using a GWAS of imputed genotype data, three of them (FUT6, MSR1 and FOXI1) were with low frequency variants (0.02 < MAF < 0.05). The associations with the RFXAP gene could not have been discovered by either GWAS or ExWAS single-point analysis.

298

299

300

301 302

303

304

305 306

307

308

309 310

311

312

313 314

315

316 317

318

319 320

321 322

323

324

325

326 327

328

329 330

331

332

333

334 335

336

337

Except for RFXAP and TIRAP, all of 8 identified genes have already been associated with IgG and transferrin glycosylation in previous GWAS studies^{17,18,20,22,23}. The novel gene TIRAP is located in close proximity to ST3GAL4, another glycosyltransferase-coding gene known to be associated with transferrin glycosylation. TIRAP has a function in the innate immune system. where it is involved in cytokine secretion and the inflammatory response^{33,34}. The lead rare variant in the mask, rs8177399 (Supplementary Table 3), in addition to being an expression OTL (eOTL) for TIRAP and several other genes, is also a splicing OTL (sOTL) for ST3GAL4 in whole blood (GTEx³⁵, p-value = 1.9x10⁻⁸). The regulatory factor X-associated protein encoded by RFXAP gene, whose variants are associated with IgG glycans, is part of a multimeric complex, called the RFX DNA-binding complex, that binds to certain major histocompatibility (MHC) class II gene promoters and activates their transcription. MHC-II molecules are transmembrane proteins, found on the surface of professional antigen-presenting cells (including B cells)³⁶, which have a central role in development and control of the immune response. While the mechanism of TIRAP's influence on the glycome could be through controlling the splicing of the known glycosyltransferase enzyme ST3GAL4, the precise role of *RFXAP* in protein glycosylation still needs to be established.

Changes in the glycosylation patterns are often observed in a wide range of pathological states. such as cancer, inflammatory, autoimmune, neurodegenerative and cardiovascular diseases³⁷ ⁴⁰. We thus assessed the potential involvement of glycome-associated genes in health, by performing, in the same three cohorts, gene-based association tests of 116 quantitative healthrelated traits, limited to genes whose rare variants we found associated with the protein glycomes. However, given the likely small effect-size of variants on complex diseases, we did not find any significant associations. On the other hand, using publicly available repositories of gene-based associations in the UK Biobank data, we found that rare missense variants from MSR1 (associated with transferrin glycosylation) were also associated with blood levels of insulin-like growth factor 1 (IGF1). IGF1 is a hormone with significant structural and functional similarities to insulin: lower levels of IGF1 are associated with higher risk of Type 1 and 2 diabetes mellitus^{41,42}. Recently, a rare deleterious missense variant in *IGF1* receptor (IGF1R) was found to be significantly associated with Type 2 diabetes in UK Biobank, further corroborating the link between IGF1 and diabetes⁴³. In addition, genetic variants in MSR1 have been previously associated with plasma levels of the galectin-3-binding protein⁴⁴. Similarly to IGF1, galectin-3 has been identified as a marker and a pathogenic factor in type 2 diabetes, with the serum protein levels increased in type 2 diabetes patients^{47–51}. An important part of iron delivery depends on recycling transferrin via clathrin-mediated endocythosis. Interestingly, binding of galectin-3 to transferrin can affect its intracellular trafficking^{45,46}. Based on the glycosylation profile, galectin-3 was found bound only to a select, minor fraction (~5%) of transferrin, while interestingly none or little was bound to IgG⁴⁶. Overall, variants from the MSR1 gene seem to have a pleiotropic effect on transferrin glycosylation, galectin-3 and IGF1. In turn, both galectin-3 and IGF1 are associated with type 2 diabetes. The potential role of glycosylation of transferrin in these processes still needs to be established.

339

340

341 342

343

344 345

346

347

348 349

350 351

352

In conclusion, we identified rare pLoF and missense variants associated with transferrin and IgG N-glycome, in both known and not previously reported genes (TIRAP, RFXAP). By utilising the power of genetic isolates and aggregated effects of rare variants, we discovered biologically relevant associations with a 300-fold up-drifted variant in the ORCADES cohort (in the sialyltransferase gene, ST6GAL1, affecting levels of sialylation of IgG) and associations independent of single-point GWAS and ExWAS analyses (in glycosyltransferase genes FUT8 and MGAT3). Interestingly, many of glycan traits are influenced both by common and rare variants, revealing a complex genetic architecture of these intermediate phenotypes. While we did not find any robust links between glycome-associated genes and diseases in studied cohorts, we discover a potential link between transferrin glycosylation, galectin-3, IGF1 and diabetes. The exact mechanism behind these connections still needs to be confirmed and further explored. This study shows that, utilising the power of genetic isolates, gene-based aggregation tests and intermediate phenotypes such as glycosylation, rare variant associations are detectable even in relatively small sample sizes (low thousands). However, larger cohorts would be required to identify the contribution of rare variants to multifactorial, complex diseases.

Methods

353

354

355

356

357

358

359 360

361

362

363

364

365 366

367 368

369

370 371

372

373

374 375

376 377

378

379

380

381

382

383

384 385

386

387

388

389

Genotypic data

Exome sequencing

The "Goldilocks" exome sequence data for ORCADES, CROATIA-Korcula and VIKING cohorts was prepared at the Regeneron Genetics Center, following the protocol detailed in Van Hout et al.² for the UK Biobank whole-exome sequencing project. In summary, the multiplexed samples were sequenced on the Illumina NovaSeq 6000 platform using S2 flow cells. The raw sequencing data was processed by automated analysis using the DNAnexus platform⁵², where files were converted to FASTO format, and then aligned to GRCh38 genome reference using the BWA-mem⁵³. Duplicated reads were identified and flagged by the Picard tool⁵⁴. Genotypes for each individual sample were called using the WeCall variant caller⁵⁵. During quality control, samples genetically identified as duplicates, showing disagreement between genetically determined and reported sex, high rates of heterozygosity or contamination, low sequence coverage (less than 80% of targeted bases achieving 20X coverage) or discordant with genotyping chip were excluded. The number of samples removed after quality control are listed in Supplementary Table 13 for each cohort. Finally, the "Goldilocks" dataset was generated by (i) filtering out genotypes with read depth lower than 7 reads, (ii) keeping variants having at least one heterozygous variant genotype with allele balance ratio greater than or equal to 15% (AB \geq 0.15) or at least one homozygous variant genotype, and (iii) filtering out variants with more than 10% of missingness and HWE p<10⁻⁶. Overall, a total of 2,090 ORCADES (820 male and 1,270 female), 2,872 CROATIA-Korcula (1,065 male and 1,807 female) and 2,108 VIKING (843 male and 1,265 female) participants passed all exome sequence and genotype quality control thresholds. A pVCF file containing all samples passing quality control was then created using the GLnexus joint genotyping tool.⁵⁶

Variant annotation

Exome sequencing variants were annotated as described in Van Hout, et al.2 In brief, each variant was labelled with the most severe consequence across all protein-coding transcripts, implemented using SnpEff⁵⁷. Gene regions were defined according to Ensembl release 85. Variants annotated as stop gained, start lost, splice donor, splice acceptor, stop lost and frameshift were considered as predicted LOF variants. The deleteriousness of missense variants was assessed using the following algorithms and classifications (based on dbNSFP 3.2): (1) SIFT: "D" (Damaging), (2) Polyphen2 HDIV: "D" (Damaging) or "P" (Possibly damaging), (3) Polyphen2_HVAR: "D" (Damaging) or "P" (Possibly damaging), (4) LRT⁵⁸: "D" (Deleterious) and (5) MutationTaster⁵⁹: "A" (Disease causing automatic) or "D" (Disease causing). Missense variants were considered "likely deleterious" if predicted as deleterious by

all five algorithms, "possibly deleterious" if predicted as deleterious by at least one of the algorithms and "likely benign" if not predicted as deleterious by any of the algorithms.

Generation of gene burden masks

390

391

392

393

394

395

396

397

398

399 400

401

402 403

404

405

406

407

408

409

410 411

412

413 414

415

416 417

418

419

420

421

422

423 424

425

For each gene, we grouped the variants in the gene in four categories (masks), based on severity of their functional consequence. Mask 1 included only predicted loss-of-function (pLoFs) variants, mask 2 consisted of pLoF variants and all missense variants, and masks 3 and 4 contained pLoF and predicted deleterious missense variants ("possibly deleterious" and "likely deleterious" for mask 3 and mask 4, respectively). We considered two separate variations of each mask based on the frequency of the minor allele of the variants that were screened in that group: $MAF \le 5\%$ and $MAF \le 1\%$. Overall, up to 8 burden tests were performed for each gene (Supplementary Table 14). Consequently, the masks are not independent - certain masks will include the variants listed in a different mask and additional, less severe or more frequent variants.

Phenotypic data

Transferrin and IgG N-glycome quantification

Transferrin and total IgG N-glycome quantification for ORCADES, VIKING and CROATIA-Korcula samples was performed at Genos Glycobiology Laboratory, following the protocol described in Trbojević-Akmačić et al. 60 for transferrin, in Pučić et al. 61 for IgG in ORCADES cohort and batch 1 of CROATIA-Korcula cohort, in Trbojević-Akmačić et al.⁶² for IgG in VIKING cohort and batch 2 of CROATIA-Korcula cohort. In summary, proteins of interest were first isolated from blood plasma (IgG depleted blood plasma, in the case of transferrin) using affinity chromatography binding to anti-transferrin antibodies plates for transferrin and protein G plates for IgG. The protein isolation step was followed by release and labelling of Nglycans and clean-up procedure.. IgG N-glycans have been released from total IgG (all subclasses). N-glycans were then separated and quantified by hydrophilic interaction ultrahigh-performance liquid chromatography (HILIC-UHPLC). As a result, transferrin and total IgG samples were separated into 35 (transferrin: TfGP1 – TfGP35) and 24 (IgG: GP1 – GP24) chromatographic peaks. It is worth noting that there is no correspondence structure-wise between transferrin TfGP and IgG GP traits labelled with the same number.

Normalisation and batch correction

Prior to genetic analysis, raw N-glycan UHPLC data was normalised and batch corrected to reduce the experimental variation in measurements. Total area normalisation was performed by dividing the area of each chromatographic peak (35 for transferrin, 24 for IgG) by the total

area of the corresponding chromatogram. Due to the multiplicative nature of measurement error and right-skewness of glycan data, normalised glycan measurements were log10-transformed. Batch correction was then performed using the empirical Bayes approach implemented in the "ComBat" function of the "sva" R package⁶³, modelling the technical source of variation (96well plate number) as batch covariate. Batch corrected measurements were then exponentiated back to the original scale. Prior to further analysis, each glycan trait was rank transformed to normal distribution using the "rntransform" function from the "GenABEL" R package⁶⁴.

Derived glycan traits

426

427

428

429

430 431

432

433

434

435 436

437

438 439

440

441

442

443

444 445

446

447 448

449

450 451

452

453

454

455

456

457

458

459

460 461

IgG derived traits analysed included those defined by Huffman et al.65, and were calculated using the glycanr R package. In addition, new derived traits were calculated for both transferrin and IgG, representing the overall presence of a certain sugar structure on the totality of transferrin/IgG N-glycan traits measured (e.g. percentage of fucosylation). These newly generated traits are expected to give a direct insight in the biological pathway involved in the addition of the sugar moiety to glycan structures. Exact formulas used for defining transferrin and IgG newly derived traits can be found in Supplementary Tables 15 and 16 respectively.

Health-related quantitative traits

To evaluate the potential effect of rare variants affecting glycome on health-related phenotypes. in the same cohorts we collected 148 health-related, quantitative traits (e.g. anthropological measurements, blood levels of proteins, metabolites and biomarkers). Excluding traits with fewer than 800 samples, a total of 116 traits were considered for analysis (75 traits for ORCADES, 79 for VIKING and 47 for CROATIA-Korcula cohort). Each health-related trait was rank transformed to normal distribution using the "rntransform" function from the "GenABEL" R package⁶⁴, followed by applying the rare-variants association pipeline described below.

Gene-based aggregation analysis

We performed variant Set Mixed Model Association Tests (SMMAT)⁶⁶ on rank-transformed glycan traits, fitting a GLMM adjusting for age, sex, sampling batch in the case of CROATIA-Korcula IgG glycan traits, and familial or cryptic relatedness by kinship matrix. The kinship matrix was estimated from the genotyped data using the 'ibs' function from GenABEL R package⁶⁴. The SMMAT framework includes 4 variant aggregate tests: burden test, sequence kernel association test (SKAT), SKAT-O and SMMAT-E, a hybrid test combining the burden test and SKAT. The 4 variant aggregate tests were performed on 8 different pools of genetic variants, called "masks", described above (Supplementary Table 14).

Discovery significance threshold was Bonferroni corrected for the approximate number of genes in the human genome, 20,000, and the number of independent glycan traits, 21 for IgG and 31 for transferrin $(0.05/20000/31 = 8.06 \times 10^{-8})$ for transferrin, $0.05/20000/21 = 1.19 \times 10^{-7}$ for IgG). The number of independent glycan traits was estimated as the number of principal components that jointly explained 99% of the total variance of transferrin/IgG glycan traits in each cohort (Supplementary Tables 17 and 18). PCA was calculated on rank-transformed glycan traits, separately for each cohort, using the "prcomp" function from "factoextra" R package⁶⁷. A gene association was considered significant if it passed the above-described Bonferroni corrected significance threshold in at least one of the 4 performed variant aggregate tests and if the cumulative allele count of the variants included in the gene was equal or higher than 10. Replication significance threshold was defined as P = 0.05 divided by the number of genes and independent glycans to be replicated. For IgG glycans, this threshold was P = 5.95×10^{-4} (P = 0.05/4 genes/21 glycans) and for transferrin glycans, this threshold was P = 3.23×10^{-4} (P = 0.05/5 genes/31 glycans).

A similar analysis plan was applied to the health-related phenotypes analysed. Variant Set 476 Mixed Model Association Tests (SMMAT)⁶⁶ was performed on rank-transformed traits, fitting 477 a GLMM adjusting for age, sex, first 20 ancestral principal components (PCs), batch covariates 478 479 when available (e.g. season, time of the day and batch/subcohort) and familial or cryptic 480 relatedness.

IgG glycome gene-based aggregation meta-analysis

Gene-based aggregation analysis of IgG glycan traits for ORCADES and VIKING cohorts was repeated following the same approach as previously described, except for the restriction that masks included only variants present in both cohorts. Since IgG GP3 was not quantified in ORCADES cohort, this glycan was excluded from the meta-analysis, bringing the total number of IgG glycan traits considered to 93. We then used the "SMMAT.meta" function of "SMMAT" R package⁶⁶ to meta-analyse, for each trait, the two studies. To identify significant results we filter results by the previously described Bonferroni-corrected significance threshold of 1.19x10⁻⁷ and by the cumulative allele count of variants included in the gene equal or higher than 10.

Genome-wide association analysis

462

463

464

465

466 467

468

469

470 471

472

473

474

475

481

482

483

484

485

486

487

488 489

490

491

492

493

494

495

496

497 498

499

Genome-wide association analyses (GWAS) between HRC-imputed genotypes and 51 transferrin N-glycan traits were performed in 948 samples from CROATIA-Korcula and 959 samples from VIKING. GWAS with 94 IgG N-glycan traits were performed in 1960 samples from ORCADES, 1866 samples from CROATIA-Korcula and 1086 samples from VIKING. The sample size of the same cohort differs between transferrin and IgG due to the different number of samples successfully measured for glycosylation of each protein. Transferrin N-

501

502

503 504

505

506 507

508

509

510

517

518

519 520

521 522

523 524

525 526

527

528

529 530

531

532

533

534

535 536

537

glycan measurements were not available in ORCADES. Rank-transformed glycan traits were adjusted for age and sex, as fixed effects, and relatedness (estimated as the kinship matrix calculated from genotyped data) as random effect in a linear mixed model, calculated using the "polygenic" function from the "GenABEL" R package⁶⁴. Since IgG N-glycan traits for the CROATIA-Korcula cohort were measured at two separate occasions, the two were considered as separate cohorts. Therefore, for CROATIA-Korcula, rank transformation was performed separately in each subcohort. Samples were then merged together for GWAS, but adding batch (subcohort number - 1 or 2) as fixed effect covariate. Residuals of covariate and relatedness correction were tested for association with Haplotype Reference Consortium (HRC) r1.1imputed SNP dosages using the RegScan v. 0.5 software, applying an additive genetic model of association.

511 The genomic control inflation factor (λ_{GC}) was calculated for each glycan and health-related 512 trait. The mean genomic control inflation factor (λ_{GC}) for IgG glycan traits was 1.002 (0.982-513 1.026) in ORCADES, 1 in CROATIA-Korcula (0.971-1.031) and 0.993 in VIKING cohort (0.972-1.017) cohort; for transferrin glycan traits λ_{GC} was 1.002 in CROATIA-Korcula (0.982-1.017)514 1.026) and 0.998 in VIKING (0.974-1.021) cohort. Overall, the confounding effects of the 515 516 family structure were correctly accounted for in our analyses.

Identification of rare variant associations independent of GWAS and ExWAS signals

To ensure that the rare variant associations identified were independent of associations with variants discoverable by a GWAS or single-point exome-wide (ExWAS) analysis, we repeated the aggregate analysis while conditioning on the sentinel SNPs from the single-variant genomewide or exome-wide analysis. First, we performed GWAS of glycan traits using the same individuals as in the analysis of the exome-sequencing data, but using as genotypes SNP dosages imputed from the HRC imputation panel, as described above. For each glycan trait we defined the sentinel SNPs as the variants having the lowest significant p-value ($p < 5x10^{-8}$) in a 1Mb window, and MAF > 1%. Then we also performed the exome-wide association analysis (ExWAS), following exactly the same protocol, but with exome sequencing data used for genotypes. We then re-run variant aggregate analysis as previously described, but with adjusting the glycan traits for the genotype of the sentinel SNPs from the GWAS/ExWAS significant loci, in addition to the other covariates listed above. The statistical significance level was determined in the same way as outlined in the main analysis above.

Replication of glycome rare associations in different cohorts and associations with healthrelated traits

To investigate whether glycome rare-variants associations were cohort specific, each significant gene-glycan trait pair from the cohort-level discovery analysis was tested for associations in the remaining cohorts. The p-value threshold for replication was set to 3.23x10⁻¹

⁴ for transferrin (0.05/31/5) and 5.95x10⁻⁴ for IgG (0.05/21/4) glycans, correcting for the number of independent glycan traits (i.e. 31 for transferrin and 21 for IgG) and the number of discovered glycome-gene pairs (i.e. 5 for transferrin and 4 for IgG in gene-based aggregation analysis).

To investigate whether the glycome associated rare-variants may also affect health-related phenotypes, we tested for association each glycome-associated gene and 116 health-related traits The significance threshold was set to 5.43x10⁻⁵, correcting for the number of healthrelated traits (116), and the number of discovered glycome-gene pairs and number of glycomeassociated genes (8).

Code availability

538 539

540

541

542

543

544

545

546

547

548

549 550

551 552

553

554

555

556 557

558

559 560

561

562 563

564

We used publicly available software tools for all analyses. These software tools are listed in the main text and in the Methods.

Data availability

There is neither Research Ethics Committee approval, nor consent from individual participants, to permit open release of the individual level research data underlying this study. The datasets generated and analysed during the current study are therefore not publicly available. Instead, the research data and/or DNA samples are available from accessQTL@ed.ac.uk on reasonable request, following approval by the QTL Data Access Committee and in line with the consent given by participants. Each approved project is subject to a data or materials transfer agreement (D/MTA) or commercial contract. The UK Biobank genotypic data used in this study were approved under application 19655, 48511 and 19655 are available to qualified researchers via the UK Biobank data access process. The expression data used for the analyses described in this manuscript were obtained from the GTEx Portal on 25/11/2022. Genebass (https://app.genebass.org/) and AstraZeneca PheWAS portal (https://azphewas.com/) were accessed on 06/12/2022.

References

565

- Maurano, M. T. et al. Systematic localization of common disease-associated variation 566 1. 567 in regulatory DNA. Science (80-.). 337, 1190–1195 (2012).
- Van Hout, C. V et al. Exome sequencing and characterization of 49,960 individuals in 568 2. the UK Biobank. Nature 586, 749–756 (2020). 569
- 570 Bomba, L. et al. Whole-exome sequencing identifies rare genetic variants associated 3. 571 with human plasma metabolites. Am. J. Hum. Genet. (2022). 572 doi:10.1016/J.AJHG.2022.04.009
- 573 Flannick, J. et al. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 4. 574 controls. *Nature* **570**, 71–76 (2019).
- 575 Jurgens, S. J. et al. Analysis of rare genetic variation underlying cardiometabolic 5. 576 diseases and traits among 200,000 individuals in the UK Biobank. Nat. Genet. 2022 577 *543* **54**, 240–250 (2022).
- 578 6. Bansal, V., Libiger, O., Torkamani, A. & Schork, N. J. Statistical analysis strategies 579 for association studies involving rare variants. Nat Rev Genet 11, 773–785 (2010).
- 580 7. Zuk, O. et al. Searching for missing heritability: Designing rare variant association 581 studies. doi:10.1073/pnas.1322563111
- 582 8. Vanhooren, V. et al. Serum N-glycan profile shift during human ageing. Exp Gerontol 583 **45**, 738–743 (2010).
- 584 9. Vilaj, M., Gudelj, I., Trbojević-Akmačić, I., Lauc, G. & Pezer, M. IgG Glycans as a 585 Biomarker of Biological Age. in Biomarkers of Human Aging 81–99 doi:10.1007/978-586 3-030-24970-0 7
- 587 10. Zabczyńska, M., Link-Lenczowski, P. & Pocheć, E. Glycosylation in Autoimmune 588 Diseases, in The Role of Glycosylation in Health and Disease (eds. Lauc, G. & 589 Trbojević-Akmačić, I.) 205–218 (Springer International Publishing, 2021). 590 doi:10.1007/978-3-030-70115-4 10
- 591 Rudman, N., Gornik, O. & Lauc, G. Altered N-glycosylation profiles as potential 11. 592 biomarkers and drug targets in diabetes. FEBS Letters **593**, 1598–1615 (2019).
- 593 12. Gudelj, I. & Lauc, G. Protein N-Glycosylation in Cardiovascular Diseases and Related 594 Risk Factors. Curr. Cardiovasc. Risk Rep. 12, (2018).
- 595 Rebelo, A. L., Chevalier, M. T., Russo, L. & Pandit, A. Role and therapeutic 13. 596 implications of protein glycosylation in neuroinflammation. Trends Mol Med 28, 270– 597 289 (2022).
- 598 14. Costa, A. F., Campos, D., Reis, C. A. & Gomes, C. Targeting Glycosylation: A New 599 Road for Cancer Drug Discovery. Trends Cancer 6, 757–766 (2020).
- 600 15. Peng, W. et al. Clinical application of quantitative glycomics. Expert Rev. Proteomics 601 **15**, 1007–1031 (2018).
- Huffman, J. E. et al. Polymorphisms in B3GAT1, SLC9A9 and MGAT5 are associated 602 16. 603 with variation within the human plasma N-glycome of 3533 European adults. *Hum.* 604 Mol. Genet. 20, 5000-5011 (2011).
- Klarić, L. et al. Glycosylation of immunoglobulin G is regulated by a large network of 605 17. 606 genes pleiotropic with inflammatory diseases. Sci. Adv. 6, eaax0301 (2020).
- 607 Landini, A. et al. Genetic regulation of post-translational modification of two distinct 18. 608 proteins. Nat. Commun. 2022 131 13, 1-13 (2022).
- Lauc, G. et al. Genomics Meets Glycomics—The First GWAS Study of Human N-609 19. 610 Glycome Identifies HNF1a as a Master Regulator of Plasma Protein Fucosylation. 611 PLoS Genet. 6, e1001256 (2010).
- Lauc, G. et al. Loci Associated with N-Glycosylation of Human Immunoglobulin G 612 20. 613 Show Pleiotropy with Autoimmune Diseases and Haematological Cancers. PLoS

- 614 Genet. 9, (2013).
- 615 21. Sharapov, S. Z. et al. Defining the genetic control of human blood plasma N-glycome using genome-wide association study. Hum. Mol. Genet. 28, 2062–2077 (2019). 616
- 617 22. Shen, X. et al. Multivariate discovery and replication of five novel loci associated with 618 Immunoglobulin G N-glycosylation. *Nat. Commun.* **8**, 447 (2017).
- Wahl, A. et al. Genome-wide association study on immunoglobulin G glycosylation 619 23. 620 patterns. Front. Immunol. 9, 277 (2018).
- 621 24. Bondt, A. et al. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass 622 spectrometric high-throughput profiling method reveals pregnancy-associated changes. 623 Mol. Cell. proteomics 13, 3029–3039 (2014).
- 624 Wuhrer, M. et al. Glycosylation profiling of immunoglobulin G (IgG) subclasses from 25. 625 human serum. *Proteomics* **7**, 4070–4081 (2007).
- 626 26. Karlsson, I., Ndreu, L., Quaranta, A. & Thorsén, G. Glycosylation patterns of selected 627 proteins in individual serum and cerebrospinal fluid samples. J. Pharm. Biomed. Anal. 628 **145**, 431–439 (2017).
- 629 Spik, G. et al. Studies on glycoconjugates. LXIV. Complete structure of two 27. 630 carbohydrate units of human serotransferrin. FEBS Lett. 50, 296–299 (1975).
- 631 Võsa, U. et al. Large-scale cis- and trans-eOTL analyses identify thousands of genetic 28. 632 loci and polygenic scores that regulate blood gene expression. Nat. Genet. 2021 539 633 **53**, 1300–1310 (2021).
- 29. Karczewski, K. J. et al. Systematic single-variant and gene-based association testing of 634 635 thousands of phenotypes in 394,841 UK Biobank exomes. Cell Genomics 2,
- 636 30. Wang, Q. et al. Rare variant contribution to human disease in 281,104 UK Biobank exomes. Nature 597, 527–532 (2021). 637
- 638 31. Povysil, G. et al. Rare-variant collapsing analyses for complex traits: guidelines and 639 applications. Nat. Rev. Genet. 20, 747–759 (2019).
- 640 Zuk, O. et al. Searching for missing heritability: Designing rare variant association 32. 641 studies. (2014). doi:10.1073/pnas.1322563111
- 642 Fitzgerald, K. A. et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 33. 643 signal transduction. *Nature* **413**, 78–83 (2001).
- 644 Horng, T., Barton, G. M. & Medzhitov, R. TIRAP: an adapter molecule in the Toll 34. 645 signaling pathway. *Nat Immunol* **2**, 835–841 (2001).
- 646 35. Aguet, F. et al. Genetic effects on gene expression across human tissues. Nature 550, 647 204-213 (2017).
- 648 36. Jones, E. Y., Fugger, L., Strominger, J. L. & Siebold, C. MHC class II proteins and 649 disease: a structural perspective. Nat Rev Immunol 6, 271–282 (2006).
- 650 Juszczak, A. et al. Plasma fucosylated glycans and C-reactive protein as biomarkers of 37. 651 HNF1A-MODY in young adult—onset nonautoimmune diabetes. Diabetes Care 42, 652 17-26 (2019).
- 653 38. Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 654 **591**, 92–98 (2021).
- 655 39. Verhelst, X. et al. Protein Glycosylation as a Diagnostic and Prognostic Marker of 656 Chronic Inflammatory Gastrointestinal and Liver Diseases. Gastroenterology 158, 95– 657 110 (2020).
- 658 40. Wittenbecher, C. et al. Plasma N-Glycans as Emerging Biomarkers of 659 Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study. 660 Diabetes Care 43, 661–668 (2020).
- 661 41. Meyer, N. M. T. et al. Low IGF1 and high IGFBP1 predict diabetes onset in 662 prediabetic patients. Eur J Endocrinol 187, 555–565 (2022).
- 663 42. Segev, Y. et al. Systemic and renal growth hormone-IGF1 axis involvement in a

- 664 mouse model of type 2 diabetes. *Diabetologia* **50**, 1327–1334 (2007).
- 665 43. Gardner, E. J. et al. Damaging missense variants in IGF1R implicate a role for IGF-1 666 resistance in the etiology of type 2 diabetes. Cell Genomics 667 doi:10.1016/j.xgen.2022.100208
- Pietzner, M. et al. Genetic architecture of host proteins interacting with SARS-CoV-2. 668 44. bioRxiv Prepr. Serv. Biol. (2020). doi:10.1101/2020.07.01.182709 669
- 670 45. Carlsson, M. C., Bengtson, P., Cucak, H. & Leffler, H. Galectin-3 guides intracellular 671 trafficking of some human serotransferrin glycoforms. J Biol Chem 288, 28398–28408 672 (2013).
- 673 46. Cederfur, C. et al. Different affinity of galectins for human serum glycoproteins: 674 galectin-3 binds many protease inhibitors and acute phase proteins. Glycobiology 18, 675 384-394 (2008).
- 676 47. Atalar, M. N. et al. Assessment of serum galectin-3, methylated arginine and Hs-CRP 677 levels in type 2 diabetes and prediabetes. *Life Sci* **231**, 116577 (2019).
- 678 48. Lin, D. et al. Galectin-3/adiponectin as a new biological indicator for assessing the risk 679 of type 2 diabetes: a cross-sectional study in a community population. Aging (Albany 680 NY) 13, 15433–15443 (2021).
- Ohkura, T. et al. Low serum galectin-3 concentrations are associated with insulin 681 49. 682 resistance in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 6, 106 683 (2014).
- 684 50. Vora, A., de Lemos, J. A., Ayers, C., Grodin, J. L. & Lingvay, I. Association of 685 Galectin-3 With Diabetes Mellitus in the Dallas Heart Study. J Clin Endocrinol Metab 686 **104**, 4449–4458 (2019).
- Weigert, J. et al. Serum galectin-3 is elevated in obesity and negatively correlates with 687 51. 688 glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 95, 1404–1411 689 (2010).
- 690 52. Reid, J. G. et al. Launching genomics into the cloud: deployment of Mercury, a next 691 generation sequence analysis pipeline. *BMC Bioinformatics* **15**, 30 (2014).
- 692 Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler 53. 693 transform. *Bioinformatics* **25**, 1754–1760 (2009).
- Institute, B. Picard Tools. (2018). 694 54.
- 695 55. PLC, G. weCall. (2018).
- 696 56. Lin, M. F. et al. GLnexus: joint variant calling for large cohort sequencing. bioRxiv 697 (2018). doi:10.1101/343970
- 698 57. Cingolani, P. et al. A program for annotating and predicting the effects of single 699 nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster 700 strain w1118; iso-2; iso-3. Fly 6, 80–92 (2012).
- 701 Chun, S. & Fay, J. C. Identification of deleterious mutations within three human 58. 702 genomes. Genome Res 19, 1553–1561 (2009).
- Schwarz, J. M., Rodelsperger, C., Schuelke, M. & Seelow, D. MutationTaster 703 59. 704 evaluates disease-causing potential of sequence alterations. Nat Methods 7, 575–576 705
- 706 60. Trbojević-Akmačić, I. et al. Chromatographic monoliths for high-throughput 707 immunoaffinity isolation of transferrin from human plasma. Croat. Chem. Acta 89, 708 203-211 (2016).
- 709 Pucić, M. et al. High throughput isolation and glycosylation analysis of IgG-variability 61. 710 and heritability of the IgG glycome in three isolated human populations. Mol. Cell. 711 Proteomics 10, M111.010090-M111.010090 (2011).
- 712 Trbojević Akmačić, I., Ugrina, I. & Lauc, G. Methods in Enzymology, Volume 586: 62. 713 Chapter Three - Comparative Analysis and Validation of Different Steps in Glycomics

714 Studies. (2017). doi:https://doi.org/10.1016/bs.mie.2016.09.027

728

- 715 63. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray 716 expression data using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).
- 717 Karssen, L. C., van Duijn, C. M. & Aulchenko, Y. S. The GenABEL Project for 64. 718 statistical genomics. F1000Research 5, 914 (2016).
- 719 Huffman, J. E. et al. Comparative Performance of Four Methods for High-throughput 65. 720 Glycosylation Analysis of Immunoglobulin G in Genetic and Epidemiological Research. Mol. Cell. Proteomics 13, 1598–1610 (2014). 721
- 722 Chen, H. et al. Efficient Variant Set Mixed Model Association Tests for Continuous 66. 723 and Binary Traits in Large-Scale Whole-Genome Sequencing Studies. Am J Hum 724 Genet 104, 260–274 (2019).
- 725 Kassambara, A. and Mundt, F. Factoextra: Extract and Visualize the Results of 67. 726 Multivariate Data Analyses. R Package Version 1.0.7. https://CRAN.R-727 project.org/package=factoextra (2020).

Acknowledgements

729

730 731

732

733

734

735

736

737 738

739

740

741

742

743

744

745

746

747

748 749

750

751

752

753

754

755

756

757

758

759

760 761

768

We thank Dr Nicola Pirastu for his help and advice regarding the statistical methods. The Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276 and CZB/4/710), the Royal Society, the MRC Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract number LSHG-CT-2006-018947). ORCADES DNA extractions and genotyping were performed at the Genetics Core of the Clinical Research Facility, University of Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Orkney, the administrative team in Edinburgh, and the people of Orkney. The CROATIA-Korcula study was funded by grants from the MRC (United Kingdom), European Commission Framework 6 project EUROSPAN (contract number LSHG-CT-2006-018947), Croatian Science Foundation (grant 8875) and the Republic of Croatia Ministry of Science, Education and Sports (216-1080315-0302). Genotyping was performed in the Genetics Core of the Clinical Research Facility, University of Edinburgh. We would like to acknowledge all the staff of several institutions in Croatia that supported the CROATIA-Korcula fieldwork, including, but not limited to, the University of Split and Zagreb Medical Schools, Institute for Anthropological Research in Zagreb, and the Croatian Institute for Public Health in Split. The Viking Health Study-Shetland (VIKING) was supported by the MRC Human Genetics Unit quinquennial programme grant 'QTL in Health and Disease'. DNA extractions and genotyping were performed at the Edinburgh Clinical Research Facility. University of Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Shetland, the administrative team in Edinburgh and the people of Shetland. We acknowledge support from the European Union's Horizon 2020 research and innovation programme IMforFUTURE (A.L. and A.F.-H.: H2020-MSCA-ITN/721815); the RCUK Innovation Fellowship from the National Productivity Investment Fund (L.K.: MR/R026408/1) and the MRC Human Genetics Unit programme grant, 'QTL in Health and Disease' (J.F.W. and C.H.: MC_UU_00007/10). Finally, this research has been conducted using data from the UK Biobank Resource (under application 26041, 48511 and 19655). For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Ethics

- All studies were approved by local research ethics committees and all participants have given 762 763 written informed consent. The ORCADES study was approved by the NHS Orkney Research
- 764 Ethics Committee and the North of Scotland REC. The CROATIA-Korcula study was
- 765 approved by the Ethics Committee of the Medical School, University of Split (approval ID:
- 766 2181-198-03-04/10-11-0008). The VIKING study was approved by the South East Scotland
- 767 Research Ethics Committee, NHS Lothian (reference: 12/SS/0151).

Author contributions

769

770

771

772

773

774

775

776

777 778

779

780

781

782

783

784

785

786

787 788

789

790 791

792

A.L.: Data analysis and interpretation, visualisation, writing—original draft preparation, writing—review and editing. P.R.H.J.T.: preparation of pipeline for gene-based aggregation test of rare variants, writing—review and editing, A.F.-H.; computation of new derived IgG glycan traits, data interpretation. I.T.-A.: Quantification of transferrin and IgG N-glycans, computation of derived transferrin glycan traits, writing—review and editing. F.V.: Glycan data quality control, T.P.: Ouantification of transferrin and IgG N-glycans, G.T.: preparation. quality control and annotation of whole-exome sequencing data, writing—review and editing. A.R.S.: Funding. O.P.: Genomic and demographic data provider for CROATIA-Korcula cohort. C.H.: Genomic and demographic data provider for CROATIA-Korcula cohort. G.L.: Conceptualisation, glycan data provider, writing—review and editing. J.F.W.: Funding, conceptualisation, genomic and demographic data provider for ORCADES and VIKING cohort, supervision, data interpretation, writing—original draft preparation, writing—review and editing. L.K.: Conceptualisation, supervision, data interpretation, writing—original draft preparation, writing—review and editing.

Competing interests

P.R.H.J.T. is an employee of BioAge Labs, Inc. G.T. and A.R.S. are full-time employees of Regeneron Genetics Center and receive salary, stock and stock options as compensation. G.L. is the founder and owner of Genos Ltd, a private research organisation that specialises in the high-throughput glycomic analysis and has several patents in this field. A.F.-H., I.T.-A., F.V., and T.P. are employees of Genos Ltd. L.K. is an employee of Humanity Inc., a company developing direct-to-consumer measures of biological ageing. All other authors declare no competing interests.